{"disease":{"id":"homologous-recombination-deficiency","name":"homologous recombination deficiency"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04190667","title":"Homologous Recombination Deficiency Status in Epithelial Ovarian Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":1300,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT05310370","title":"HRD and Resistance to PAPPi in EOC Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT04651920","title":"A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":240,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT06545942","title":"Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":220,"lead_sponsor_name":"MOMA Therapeutics","has_results":false},{"nct_id":"NCT04651933","title":"A Training Set for the HRD Model in EOC","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT04174716","title":"Basket Trial of IDX-1197, a PARP Inhibitor, in Patients With HRR Mutated Solid Tumors (VASTUS)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":108,"lead_sponsor_name":"Idience Co., Ltd.","has_results":false},{"nct_id":"NCT07303218","title":"The HER Project: HRD in EGFR-mutated NSCLC","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT07113964","title":"QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":79,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT04515836","title":"Olaparib in Patients With HRD Malignant Mesothelioma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT05461690","title":"Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false},{"nct_id":"NCT04556071","title":"Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":32,"lead_sponsor_name":"Xiaoxiang Chen","has_results":false},{"nct_id":"NCT06095141","title":"Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT03522064","title":"Bipolar Androgen Therapy + Carboplatin in mCRPC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"St Vincent's Hospital, Sydney","has_results":false},{"nct_id":"NCT05732129","title":"The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":29,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04780945","title":"Functional Analysis of BRCAness","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":27,"lead_sponsor_name":"Leiden University Medical Center","has_results":false},{"nct_id":"NCT03209401","title":"Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":23,"lead_sponsor_name":"Georgetown University","has_results":false},{"nct_id":"NCT03442556","title":"Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":18,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT03712930","title":"Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":13,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT06527690","title":"Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Latin American Cooperative Oncology Group","has_results":false},{"nct_id":"NCT03432676","title":"Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false}],"total":20},"guidelines":[],"source":"Drug Landscape verified database"}